Tharimmune Commits $540M to Canton Coin Treasury: Significant Investment in Future Expansion

Written by Ohris M. Greyoon, Blockchain & Crypto Expert

CC+3.32%

CFG-2.56%

Source: Coinmarketcap

Updated: Nov 03 2025

Tharimmune's Major Funding: Biotech firm Tharimmune has raised $540 million in a private funding round to enhance its cryptocurrency strategy, including plans to acquire Canton Coin and operate as a Super Validator on the Canton Network.
Institutional Support: The funding was led by DRW and Liberty City Ventures, with participation from notable investors like ARK Invest and Kraken, reflecting strong institutional confidence in the integration of biotech and blockchain.
Market Response: Following the announcement, Tharimmune's stock saw a positive reaction, gaining approximately 14% in after-hours trading, indicating investor optimism about the company's venture into blockchain and decentralized finance.
Broader Financial Trends: The article highlights the growing intersection of traditional finance and blockchain technology, with tokenized assets exceeding $34 billion, showcasing a shift towards digital asset management and interoperability in financial applications.

About the author

Ohris M. Greyoon

Ohris M. Greyoon holds a Master’s in Computer Science from MIT and has 10 years of experience in blockchain technology and cryptocurrency markets. A pioneer in decentralized finance (DeFi) analysis, he leads Intellectia’s Crypto News, offering cutting-edge insights into digital assets.

Tharimmune Commits $540M to Canton Coin Treasury: Significant Investment in Future Expansion

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Viavi Solutions Reports Strong Q2 2026 Earnings with Growth Momentum

Landstar System Q4 2025 Earnings Call Insights

People Also Watch